| P2093 | author name string | Robert I Grundy | |
| P2860 | cites work | Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 |
| | Molecular cloning of a human cannabinoid receptor which is also expressed in testis | Q24337626 |
| | Cannabinoid receptor localization in brain | Q24558751 |
| | Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker | Q24601670 |
| | Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors | Q24642509 |
| | Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants | Q24685540 |
| | Cannabinoids control spasticity and tremor in a multiple sclerosis model | Q28138564 |
| | Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor | Q28218654 |
| | Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 |
| | Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1 | Q28270721 |
| | Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 |
| | Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60 | Q28374277 |
| | Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata | Q28377147 |
| | The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-Δ6-tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates receptor-mediated neurotoxicity in primary cultures of rat forebrain | Q29012303 |
| | Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 |
| | Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development | Q31522100 |
| | The cannabinoid system and cytokine network | Q34040002 |
| | An endogenous cannabinoid (2-AG) is neuroprotective after brain injury | Q34093755 |
| | Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties | Q34133453 |
| | Cerebral ischemia and inflammation | Q34139882 |
| | The role of cannabinoids in neurodegenerative diseases | Q34268475 |
| | Cannabinoids and neuroprotection | Q34520143 |
| | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 |
| | Pharmacological interventions for stroke: failures and future | Q34628650 |
| | Tetrahydrocannabinol for tremor in multiple sclerosis | Q34708416 |
| | Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 |
| | In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum | Q35028193 |
| | Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells | Q37599138 |
| | Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. | Q40743568 |
| | Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant | Q41355460 |
| | Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity | Q42478605 |
| | Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice | Q42490465 |
| | Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. | Q42517324 |
| | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 |
| | Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. | Q43611998 |
| | Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease | Q43669613 |
| | Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 |
| | Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity | Q43713675 |
| | Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. | Q43742950 |
| | Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration | Q43752352 |
| | Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 |
| | Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. | Q44330257 |
| | Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis | Q44929830 |
| | Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. | Q45289172 |
| | The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 |
| | Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease | Q45305400 |
| | The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway | Q45753821 |
| | Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes | Q45761757 |
| | Cannabinoid receptors and immunity | Q48029970 |
| | A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. | Q48366948 |
| | Nabilone in the treatment of multiple sclerosis. | Q55065083 |
| | Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish | Q55871276 |
| | Cannabinoid CB1 Receptor Expression in Rat Spinal Cord | Q56827591 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 1365-1374 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | The therapeutic potential of the cannabinoids in neuroprotection | |
| P478 | volume | 11 | |